Peptide therapy for treatment of allergic diseases

Clinical Immunology and Immunopathology

Volumn 80, Issue 2, 1996, Pages 105-109

  Wallner, Barbara P ^a   Gefter, Malcolm L ^a  

^a ImmuLogic Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYTOKINE; IMMUNOGLOBULIN E; SYNTHETIC PEPTIDE;

ALLERGY; CLINICAL TRIAL; HUMAN; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030222373     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.0102     Document Type: Review

References (51)

1. 1. O'Hehir, R. E., Bal, V., Quint, D., Moqbel, R., Kay, A. B., Zanders, E. D., and Lamb, J. R., An in vitro model of allergen-dependent IgE synthesis by human B lymphocytes: Comparison of the response of an atopic and a non-atopic individual to Dermatophagoides spp. (house dust mite). Immunology 66, 499-504, 1989.
2. + T lymphocytes in atopic patients. J. Immunol. 144, 4651-4656, 1990.
3. 3. Plaut, M., Antigen-specific lymphokine secretory patterns in atopic disease. J. Immunol. 144, 4497-4500, 1990.
4. 4. Parronchi, P., Macchia, D., and Piccinni, M. P., Allergen-and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc. Natl. Acad. Sci. USA 88, 4538-4542, 1991.
5. 5. Kasaian, M. T., Meyer, C. H., Nault, A. K., and Bond, J. F., An increased frequency of IgE-producing B cell precursors contributes to the elevated levels of plasma IgE in atopic subjects. Clin. Exp. Allergy 25, 749-755, 1995.
6. 6. Owen, W. F., Jr., and Austen, K. F., Cytokine regulation of eosinophil-mediated inflammatory reactions by modulation of eosinophil programmed cell death and subsequent priming for augmented functions. In "Eosinophils in Allergy and Inflammation" (G. J. Gleich and A. B. Kay, Eds.), pp. 239, Dekker, New York, 1994.
7. 7. Creticos, P. S., Immunologic changes associated with immunotherapy. In "Immunology and Allergy Clinics of North America: Immunotherapy of IgE-Mediated Disorders" (P. A. Greenberger, Ed.), pp. 13-37, Saunders, Philadelphia, 1992.
8. 8. McHugh, S. M., Lavelle, B., Kemeny, D. M., Patel, S., and Ewan, P. W., A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J. Allergy Clin. Immunol. 86(4), 521-531, 1990.
9. 9. Lichtenstein, L. M., Ishizaka, K., Norman, P. S., Subotka, A. K., and Hill, B. M., IgE antibody measurements in ragweed hay fever: Relationship to clinical severity and the results of immunotherapy. J. Clin. Invest. 52, 472-482, 1973.
10. 10. Greenstein, J. L., Morgenstern, J. P., LaRaia, J., Counsell, C. M., Goodwin, W. H., Lussier, A., Creticos, P. S., Norman, P. S., and Garman, R. D., Ragweed immunotherapy decreases T cell reactivity to recombinant Amb aI.1. J. Allergy Clin. Immunol. 89, 322, 1992. [Abstract]
11. 11. Secrist, H., Chelen, C. J., Wen, Y., Marshall, J. D., and Umetsu, D. T., Allergen immunotherapy decreases interleukin-4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 178, 2123-2130, 1993.
12. 12. Varney, V. A., Hamid, Q. A., Gaga, M., Ying, S., Jacobson, M., Frew, A. J., Kay, A. B., and Durham, S. R., Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J. Clin. Invest. 92, 644-651, 1993.
13. 13. Jutel, M., Pichler, W. J., Kkrbic, D., Urwyler, A., Dahinden, C., and Muller, U. R., Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFNγ secretion in specific allergen-stimulated T cell cultures. J. Immunol. 154, 4187-4194, 1995.
14. 14. Tokushima, M., Sanz, M. L., de las Marinas, M. D., and Oehling, A., Lymphocyte response to IgE regulatory factors in allergic patients during the course of immunotherapy. Allergol. Immunopathol. (Madr.) 18(2), 69-74, 1990.
15. 15. Gefter, M. L., A new generation of antigens for immunotherapy. In "Current therapy in Allergy, Immunology, and Rheumatology" (L. M. Lichtenstein and A. Fauci, Eds.), pp. 376-378, Mosby, St. Louis, MO, 1992.
16. 16. Litwin, A., Pesce, A. J., Fisher, T., Michael, M., and Michael, J. G., Regulation of the human immune response to ragweed pollen by immunotherapy. A controlled trial comparing the effect of immunosuppressive peptic fragments of short ragweed with standard treatment. Clin. Exp. Allergy 21, 457-465, 1991.
17. 17. Scherer, M. T., Chan, B. M. C., Ria, F., Smith, J. A., Perkins, D. L., and Gefter, M. L., Control of cellular and humoral immune responses by peptides containing T-cell epitopes. Cold Spring Harbor Symp. Quant. Biol. 54, 497-504, 1989.
18. 18. Gammon, G., Sercarz, E. E., and Benichou, G.,The dominant self and the cryptic self; Shaping the autoreactive T-cell repertoire. Immunol. Today 12, 193-195, 1991.
19. 19. Ria, F., Chan, B. M., Scherer, M. T., Smith, J. A., and Gefter, M. L., Immunological activity of covalently linked T-cell epitopes. Nature (London) 343, 381-383, 1990.
20. 20. Lamb, J. R., Skidmore, B. J., Green, N., Chiller, J. M., and Feldmann, M., Induction of tolerance in influenza virus immune T lymphocyte clones with synthetic peptides of influenza haemagglutinin. J. Exp. Med. 157, 1434-1447, 1983.
21. 21. Briner, T. J., Kuo, M-C., Keating, K. M., Rogers, B. L., and Greenstein, J. L., Peripheral T cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen. Proc. Natl. Acad. Sci. USA 90, 7608-7612, 1993.
22. 22. Schwartz, R. H., A cell culture model for T lymphocyte clonal anergy. Science 248, 1349, 1990.
23. 23. Mueller, D. L., Jenkins, M. K., and Schwartz, R. H., Clonal expansion versus functional clonal inactivation: A costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7, 445-480, 1989.
24. 24. Shahinian, A., Pfeffer, K., Lee, K. P., Kündrig, T. M., Kishihara, K., Wakeman, A., Kawai, K., Ohashi, P., Thompson, C. B., and Mak, T. W., Differential T cell costimulatory requirements in CD28-deficient mice. Science 261, 609-612, 1993.
25. c chain of the IL-2 receptor. Science 266, 1039-1042, 1994.
26. 26. Lucas, P. J., Negishi, I., Nakayama, K., Fields, L. E., and Loh, D. Y., Naive CD28-deficient T Cells can initiate but not sustain an In vitro antigen-specific immune response. J. Immunol. 154, 5757-5768, 1995.
27. 27. Rincón, M., and Flavell, R. A., AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 13(18), 4370-4381, 1994.
28. 28. Miller, G. T., Hochman, P. S., Meier, W., Tizard, R., Bixler, S. A., Rosa, M. D., and Wallner, B. P., Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J. Exp. Med. 178, 211-222, 1993.
29. 29. Samson, M. F., and Smilek, D. E., Reversal of acute experimental autoimmune encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analogue modified to form long-lived peptide-MHC complexes. J. Immunol. 155, 2737-2746, 1995.
30. 30. Gaur, A., Wiers, B., Liu, A., Rothbard, J., and Fathman, C. G., Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258, 1491, 1992.
31. 31. Ku, G., Kronenberg, M., Peacock, D. J., Tempst, P., Banquerigo, M. L., Braun, B. S., Reeve, J. R., Jr., and Brahn, E., Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur. J. Immunol. 23, 591-599, 1993.
32. 32. Aichele, P., Kyburz, D., Ohashi, P. S., Odermatt, B., Zinkernagel, R. M., Hengartner, H., and Pircher, H., Peptide-induced T-cell tolerance to prevent autoimmune diabetes in transgenic mouse model. Proc. Natl. Acad. Sci. USA 91, 944, 1994.
33. 33. Moskophidis, D., Lechner, F., Pircher, H., and Zinkernagel, R. M., Virus persistence in acutely infected immuno-competent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (London) 362, 758-761, 1993.
34. 34. Rocha, B., Grandien, A., and Freitas, A. A., Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med. 181, 993-1003, 1995.
35. 35. Critchfield, J. M., Racke, M. K., Zuniga-Pflücker, J. C., Cannella, B., Raine, C. S., Goverman, J., and Lenardo, M. J., T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263, 1139-1142, 1994.
36. 36. Khare, S. D., Krco, C. J., Griffiths, M. M., Harvinder, S. L., and David, C. S., Oral administration of immunodominant human collagen peptide modulates collagen-induced arthritis. J. Immunol. 155, 3653-3659, 1995.
37. 37. Hoyne, G. F., Callow, M. G., Kuo, M-C., and Thomas, W. R., Inhibition of T-cell responses by feeding peptides containing major and cryptic epitopes: Studies with the Der p I allergen. Immunology 83, 190-195, 1994.
38. 38. Hoyne, G. F., O'Hehir, R. E., Wraith, D. C., Thomas, W. R., and Lamb, J. R., Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178, 1783-1788, 1993.
39. 39. Wallner, B. P., and Gefter, M. L., Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy 49, 302-308, 1994.
40. 40. Norman, P. S., Ohman, J. L., Long, A. A., Creticos, P. S., Gefter, M. L., Shaked, Z., Wood, R. A., Eggleston, P. A., Lichtenstein, L. M., Jones, N. H., and Nicodemus, C. F., Follow on study of the first clinical trial with T cell defined peptides from cat allergen Fe1 dI. J. Allergy Clin. Immunol. 95(1), 259, 1995. [Abstract]
41. 41. Nonaka, M., Nonaka, R., Woolley, K., Adelroth, E., Miura, K., Okhawara, Y., Glibetic, M., Nakano, K., O'Byrne, P., Dolovich, J., and Jordana, M., Distinct immunohistochemical localization of IL-4 in human inflammed airway tissues. J. Immunol. 155, 3234-3244, 1995.
42. 42. Thompson-Snipes, L., Dhar, V., Bond, M. W., Mosmann, T. R., Moore, K. W., and Rennick, D., Interleukin-10: A novel stimulatory factor for mast cells and their progenitors. J. Exp. Med. 173, 507-510, 1991.
43. 43. Seminario, M-C., and Gilrich, G. J., The role of eosinophils in the pathogenesis of asthma. Curr. Opin. Immunol. 6, 860-864, 1994.
44. 44. Ohnishi, T., Kita, H., Weiler, D., Sur, S., Sedgwick, J. G., Calhoun, W. J., Busse, W. W., Abrams, S. S., and Gileich, G. J., IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late phase reaction. Am. Rev. Respir. Dis. 147, 901-907, 1993.
45. 45. Schleimer, R. P., Derse, C. P., Friedman, B., Gillis, S., Plaut, M., Lichtenstein, L. M., and MacGlashan, D. W., Jr., Regulation of human basophil mediator release by cytokines. I. Interaction with antiinflammatory steroids. J. Immunol. 143, 1310-1317, 1989.
46. 46. Woodman-Filipowicz, A., Heusser, C. H., and Moroni, C., Production of the haemopoietic growth factors GM-CSF and interleukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 339, 150-152, 1989.
47. 47. Burd, P. R., Rogers, H. W., Gordon, J. R., Martin, C. A., Jayaraman, S., Wilson, S. D., Dvorak, A. M., Galli, S. J., and Dorf, M. E., Interleukin 3-dependent and -independent mast cells stimulated with IgE and antigen express multiple cytokines. J. Exp. Med. 170, 245-257, 1989.
48. 48. Chen, X. J., and Enerbach, L., IgE receptors, IgE content and secretory response of mast cells in athymic rats. Immunology 83, 595-600, 1994.
49. 49. Frew, A. J., and Kay, A. B., The relationship between infiltrating CD4+ lymphocytes, activated eosinophils and the magnitude of the allergen-induced late phase cutaneous reation. J. Immunol. 141, 4158-4164, 1988.
50. 50. Varney, V. A., Jacobson, M. R., Sudderick, R. M., Robinson, D. S., Irani, A. M., Schwartz, L. B., Mackay, I. S., Kay, A. B., and Durham, S. R., Immunohistology of the nasal mucosa following allergen-induced rhinitis. Identification of activated T lymphocytes, eosinophils, and neutrophils. Am. Rev. Respir. Dis. 146(1), 170-176, 1992.
51. 51. Moller, A., Lippert, U., Lessman, D., Kolde, G., Hamann, K., Welker, P., Schadendorf, D., Rosenback, T., Luger, T., and Czarnezki, B. M., Human mast cells produce IL-8. J. Immunol. 151, 3261-3266, 1993.